long intergenic non-protein coding RNA 2420Genealiases: []
Q-omics provides the consensus-scored LINC02420 profile across patient tissues and cancer cell-line models. LINC02420 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC02420 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, LINC02420 RNA expression shows 6,703 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where LINC02420 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02420 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02420 survival associations across molecular data types. LINC02420 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02420 RNA expression–survival associations across cancer types. High LINC02420 expression shows unfavorable associations in KICH, STAD, COAD, THYM, MESO and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC02420 RNA expression.
This table summarizes LINC02420 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02420. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02420 shows lower tumor expression in COAD and higher tumor expression in BRCA and THCA. The BRCA box plot shows higher LINC02420 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .001).
This table shows molecular features associated with LINC02420 in patient tissues and cancer cell lines. In patient samples, LINC02420 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
